AstraZeneca’s Flumist for Annual Flu is now Available
The CDC and the FDA have updated their recommendations for the 2021-2022 flu season.
AstraZeneca has announced the U.S. availability of Flumist Quadrivalent (influenza vaccine live) for the 2021-2022 influenza season. This nasal-spray flu vaccine is indicated for people ages 2 through 49. The bulk of AstraZeneca’s supply for the 2021-2022 flu season is expected to be available by mid-September.
Mina Makar
“As the world continues to navigate an unpredictable public health landscape with coinciding flu and COVID-19 viruses, AstraZeneca remains committed to following the science and putting people and their communities first by helping ensure families have access to a needle-free vaccination option,” Mina Makar, senior vice president, U.S. respiratory and immunology at AstraZeneca, said in a statement.
Flumist Quadrivalent is the only FDA-approved flu vaccine to use a needle-free nasal spray administrative technique. AstraZeneca’s live attenuated influenza vaccine (either as trivalent or quadrivalent formulations) has been approved by the FDA since 2003.
In line with the 2021-2022 recommendations from the CDC’s Advisory Committee on Immunization Practices recommends the flu vaccine for everyone six months and older. Nasal spray vaccines are not recommended for children younger than two years or older than 50 years, or anyone who is immune compromised.
This season, all flu vaccines will be designed to protect against the four viruses that research indicates will be most common, according to the CDC. This year, a few things are new, including the composition of the flu vaccines has been updated, and the licensure on one flu vaccine has changed. Flucelvax Quadrivalent is now approved for people 2 years and older.
The CDC indicated that this year, there were fewer flu viruses available to inform the selection process, but officials don’t believe this will impact the match between circulating viruses and the vaccines available.
The FDA has released a list of the available flu vaccines as of August 26, 2021.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
